Amneal Pharmaceuticals Statistics
Amneal Pharmaceuticals (2DT) Stock Statistics & Valuation Metrics
Total Valuation
Amneal Pharmaceuticals has a market cap or net worth of EUR 6.80B. The enterprise value is EUR 9.98B.
- Market Cap
- EUR 6.80B
- Enterprise Value
- EUR 9.98B
Share Statistics
Amneal Pharmaceuticals has 348,412,720 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 348,412,720
- Owned by Insiders
- 36.76%
- Owned by Institutions
- 46.50%
Financial Efficiency
Amneal Pharmaceuticals’s return on equity (ROE) is -1.02 and return on invested capital (ROIC) is 13.80%.
- Return on Equity (ROE)
- -1.02
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 13.80%
- Return on Capital Employed (ROCE)
- 0.15
- Revenue Per Employee
- 346.98K
- Profits Per Employee
- 8,282.414
- Employee Count
- 8,700
- Asset Turnover
- 0.82
- Inventory Turnover
- 3.11
Valuation Ratios
The current PE Ratio of Amneal Pharmaceuticals is 49.74. Amneal Pharmaceuticals’s PEG ratio is 0.02.
- PE Ratio
- 49.74
- PS Ratio
- 2.33
- PB Ratio
- 13.52
- Price to FCF
- 184.45
- Price to Operating Cash Flow
- 39.33
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Amneal Pharmaceuticals had revenue of 3.02B and earned 72.06M in profits. Earnings per share was 0.23.
- Revenue
- 3.02B
- Gross Profit
- 1.14B
- Operating Income
- 423.09M
- Pretax Income
- 139.21M
- Net Income
- 72.06M
- EBITDA
- 603.87M
- Earnings Per Share (EPS)
- 0.23
Cash Flow
In the last 12 months, operating cash flow was 182.61M and capital expenditures -142.20M, giving a free cash flow of 40.41M billion.
- Operating Cash Flow
- 182.61M
- Free Cash Flow
- 40.41M
- Free Cash Flow per Share
- 0.12
Dividends & Yields
Amneal Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.54%
- Earnings Yield
- 2.06%
Stock Price Statistics
- Beta
- 0.71
- 52-Week Price Change
- 96.94%
- 50-Day Moving Average
- 17.16
- 200-Day Moving Average
- 13.66
- Relative Strength Index (RSI)
- 63.84
- Average Volume (3m)
- 101
Important Dates
Amneal Pharmaceuticals upcoming earnings date is Feb 26, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Feb 26, 2027
- Ex-Dividend Date
- ―
Financial Position
Amneal Pharmaceuticals as a current ratio of 2.17, with Debt / Equity ratio of -3865.40%
- Current Ratio
- 2.17
- Quick Ratio
- 1.48
- Debt to Market Cap
- 0.67
- Net Debt to EBITDA
- 4.02
- Interest Coverage Ratio
- 1.75
Taxes
In the past 12 months, Amneal Pharmaceuticals has paid 11.28M in taxes.
- Income Tax
- 11.28M
- Effective Tax Rate
- 0.08
Enterprise Valuation
Amneal Pharmaceuticals EV to EBITDA ratio is 15.82, with an EV/FCF ratio of 261.46.
- EV to Sales
- 3.31
- EV to EBITDA
- 15.82
- EV to Free Cash Flow
- 261.46
- EV to Operating Cash Flow
- 57.85
Balance Sheet
Amneal Pharmaceuticals has EUR 157.40M in cash and marketable securities with EUR 3.28B in debt, giving a net cash position of -EUR 3.13B billion.
- Cash & Marketable Securities
- EUR 157.40M
- Total Debt
- EUR 3.28B
- Net Cash
- -EUR 3.13B
- Net Cash Per Share
- -EUR 8.97
- Tangible Book Value Per Share
- -EUR 5.01
Margins
Gross margin is 40.24%, with operating margin of 15.61%, and net profit margin of 4.62%.
- Gross Margin
- 40.24%
- Operating Margin
- 15.61%
- Pretax Margin
- 6.93%
- Net Profit Margin
- 4.62%
- EBITDA Margin
- 20.90%
- EBIT Margin
- 14.84%
Analyst Forecast
The average price target for Amneal Pharmaceuticals is EUR 22.53, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 22.53
- Price Target Upside
- 16.72% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 3.60%
- EPS Growth Forecast
- 2761.42%
Scores
- Smart Score
- 10
- AI Score
- ―

